Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.

Timeline

Start

2009-03

Primary completion

2013-03

Completion

2016-12

Outcome

Outcome not reported

Stopped (Business): “Funding unavailable”

Drugs

Indications